BRIEF published on 11/10/2025 at 21:55, 1 month 4 days ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 1 month 4 days ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 2 months 21 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 2 months 21 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 7 months ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 7 months ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
BRIEF published on 02/13/2025 at 22:00, 10 months 1 day ago Integrated BioPharma Reports Quarterly Results with Increased Revenue Revenue Growth Q4 Results Operating Income Customer Base Expansion Integrated BioPharma
PRESS RELEASE published on 02/13/2025 at 21:55, 10 months 1 day ago Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024 Integrated BioPharma, Inc. reports 9.6% increase in revenue to $12.6 million for quarter ended Dec 31, 2024. Operating income of $0.2 million. Detailed financial results provided Financial Results Revenue Increase Quarterly Report Operating Income Integrated BioPharma
BRIEF published on 11/13/2024 at 23:38, 1 year 1 month ago Integrated BioPharma, Inc. Announces Q3 2024 Financial Results Revenue Growth Net Income Integrated BioPharma Customer Diversification Q3 2024 Results
PRESS RELEASE published on 11/13/2024 at 23:33, 1 year 1 month ago Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024 Integrated BioPharma, Inc. reports revenue growth in Q3 2024 with net income of $0.3 million. Diversification of customer base leads to increased financial performance Revenue Growth Financial Performance Diversification Q3 2024 Integrated BioPharma
Published on 12/15/2025 at 15:00, 1 hour 7 minutes ago Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 1 hour 7 minutes ago Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 1 hour 37 minutes ago Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 2 hours 7 minutes ago Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum
Published on 12/15/2025 at 13:30, 2 hours 37 minutes ago Greenlane Announces Results of Annual Meeting of Stockholders, Canopy Growth Co Founder Bruce Linton Joins Greenlane's Board of Directors
Published on 12/15/2025 at 15:50, 17 minutes ago Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen
Published on 12/15/2025 at 15:49, 18 minutes ago Mutares submits an irrevocable offer to acquire Venator Ultramarine Blue Pigments business from Venator France SAS
Published on 12/15/2025 at 15:45, 22 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/15/2025 at 15:44, 23 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/15/2025 at 15:43, 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 12/15/2025 at 11:50, 4 hours 17 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 22 hours ago Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/11/2025 at 08:30, 4 days 7 hours ago Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe
